ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥ 60 Years of Age
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 4
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 60+ years of Age
- Signed an informed consent prior to the start of study
- Non-Feverish, (less than 101.0°F / 38.3°C) on day of vaccination
- Females must be postmenopausal or have a negative pregnancy test
Exclusion Criteria:
- A history of allergic reaction to any vaccine component (including gelatin or neomycin)
- Prior receipt of any varicella or zoster vaccine
- Any live virus vaccine administered within 4 weeks before the start of the study or scheduled during the 42 days after vaccination
- Any inactivated virus vaccine, except for flu vaccine, administered within 7 days before the start of the study or scheduled during the 42 days after vaccination
- Subject is pregnant or breastfeeding
- Participation in an investigational drug or vaccine study within the last 30 days prior to the start of the study or expected during the 42 days after vaccination
- An ongoing illness (including active untreated tuberculosis) that might interfere with or prevent the subject from completion of the study
- Use of immunosuppressive therapy. Subjects taking corticosteroids such as prednisone should be excluded. Excluded immunosuppressive therapies also include chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation
- Known or suspected immune dysfunction that is caused by a medical condition or any other cause. Examples of medical conditions associated with immune dysfunction include congenital immunodeficiency, human immunodeficiency virus (HIV) infection, organ or bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, or generalized malignancy. Subjects with a history of cancer who are not on active treatment and are not thought to have a weakened immune system at the time of enrollment will be eligible
- Any active use of non-topical antiviral therapy including but not limited to acyclovir, famciclovir, valacyclovir, ganciclovir, foscarnet, brivudine, and cidofovir
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:1
Arm 1: vaccine
|
single 0.65 mL Zoster Vaccine, Live injection.
6 month treatment period.
|
プラセボコンパレーター:2
Arm 2: Placebo Comparator
|
single 0.65 mL Placebo injection.
6 month treatment period.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Serious Adverse Events Reported Within 42 Days Postvaccination
時間枠:42 Days
|
Only Serious Adverse Events were collected and analyzed for this study. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. |
42 Days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Serious Adverse Events Reported Within 6 Months (Day 1 to 182) Postvaccination
時間枠:6 months
|
Only Serious Adverse Events were collected and analyzed for this study. A serious adverse event is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. |
6 months
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- V211-020
- 2007_606
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Zoster Vaccine, Liveの臨床試験
-
Serum Institute of India Pvt. Ltd.PATH完了
-
University Medical Center GroningenGGZ Drenthe Mental Health Institution募集
-
GlaxoSmithKline完了帯状疱疹アメリカ, オーストラリア, ドイツ, スペイン, 日本, 台湾, スウェーデン, 大韓民国, 香港, メキシコ, カナダ, フランス, イタリア, ブラジル, エストニア, イギリス, チェコ, フィンランド
-
University of Maryland, BaltimoreMedical Technology Enterprise Consortium (MTEC)完了
-
U.S. Army Medical Research and Development CommandState University of New York - Upstate Medical University完了
-
State University of New York - Upstate Medical...Walter Reed Army Institute of Research (WRAIR); U.S. Army Medical Research and Development Command完了
-
State University of New York - Upstate Medical...U.S. Army Medical Research and Development Command; Janssen Pharmaceutica N.V., Belgium完了
-
Johns Hopkins UniversityCenters for Disease Control and Prevention完了